"We've had absolute confidence in the efficacy of the vaccine. Seeing this data now I hope gives others increased confidences that this is a very safe and effective vaccine," Pangalos said.
The phase III interim results show 141 cases of symptomatic COVID-19 in the study of 32,449 adults."We don't have the whole breakdown yet … these are the high-level results we just got this week," Pangalos said. Further information on rates of mild to moderate COVID-19 illness between groups is not yet available, for example.
Experts welcomed the 80% efficacy in people 65 and older in particular."Importantly, the trial provides further support for efficacy in the elderly where previous clinical trial data, other than immunologic data, had been lacking," Garrett said. "What I can say is given this study was conducted much later in terms of timing, it's very encouraging that we've got such high efficacy numbers when undoubtedly there are variants of concern in circulation in this study," Pangalos said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.